CATX Perspective Therapeutics, Inc.
Price Chart
Executive Summary
Perspective Therapeutics announced updated interim results from its Phase 1/2a trial of [212Pb]VMT-α-NET in neuroendocrine tumors, showing a 43% objective response rate in Cohort 2 with continued favorable safety and deepening responses over time. The data, presented at AACR 2026, includes additional follow-up since prior disclosures at ASCO-GI and ESMO.
Actionable Insight
The sustained response rate and clean safety profile support potential for accelerated development and future regulatory engagement. Traders should monitor upcoming data from Cohort 3 and any regulatory feedback later this year as next catalysts.
Key Facts
- 43% (10 out of 23) objective response rate in Cohort 2 at 5.0 mCi dose level
- No dose-limiting toxicities, treatment-related discontinuations, or serious renal complications reported
- 9 patients experienced deepening of response since ESMO 2025 data cut
- Safety data includes 64 patients across three cohorts with no Grade 5 events
- Additional efficacy data from Cohort 3 expected later in 2026
Financial Impact
Non-financial clinical update, but materially positive for valuation potential given response rate and safety profile in a targeted oncology indication
Risk Factors
- Early-phase data — results may not translate in larger trials
- Regulatory path remains uncertain without Phase 3 plans confirmed
- High market expectations could lead to sell-on-news reaction if next data readout is delayed or muted
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276793 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
3d ago
|
Institutional Cluster
| $2.96 awaiting T+1 | awaiting T+1 | — | $2.95 (−0.34%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $2.96 awaiting T+1 | awaiting T+1 | — | $2.95 (−0.17%) |
|
Jun 3, 2026
11d ago
|
Press Release
| $3.56 $3.25 | ▼ −8.71% | ▼ −9.11% | $2.95 (−17.13%) |
|
Jun 1, 2026
13d ago
|
8-K
| $3.66 $3.60 | ▼ −1.64% | ▼ −1.78% | $2.95 (−19.40%) |
|
May 21, 2026
24d ago
|
Press Release
| $3.98 $4.16 | ▲ +4.52% | ▲ +3.94% | $2.95 (−25.88%) |
|
May 18, 2026
27d ago
|
Press Release
| $3.76 $3.63 | ▼ −3.46% | ▼ −2.81% | $2.95 (−21.54%) |
|
May 11, 2026
4w ago
|
8-K
| $3.77 $3.77 | · 0.00% | ▼ −0.54% | $2.95 (−21.75%) |
|
May 4, 2026
5w ago
|
8-K
| $3.65 $3.82 | ▲ +4.66% | ▲ +3.27% | $2.95 (−19.18%) |
|
Apr 24, 2026
7w ago
|
Press Release
| $4.51 $4.27 | ▼ −5.32% | ▼ −5.49% | $2.95 (−34.59%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $4.55 $4.64 | ▲ +1.98% | ▲ +2.63% | $2.95 (−35.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access